280 related articles for article (PubMed ID: 27241061)
1. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
Imatoh T; Sai K; Saito Y
J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
Schuck RN; Grillo JA
AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
[TBL] [Abstract][Full Text] [Related]
7. Applications of pharmacogenomics in regulatory science: a product life cycle review.
Tan-Koi WC; Leow PC; Teo YY
Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
[TBL] [Abstract][Full Text] [Related]
8. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
9. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Vivot A; Boutron I; Ravaud P; Porcher R
Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
[TBL] [Abstract][Full Text] [Related]
11. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
[TBL] [Abstract][Full Text] [Related]
12. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006-2018).
Seo Y; Pacifici E
Vaccine; 2020 Nov; 38(47):7485-7489. PubMed ID: 33059971
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
[TBL] [Abstract][Full Text] [Related]
14. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
Hafner S; Haubensak S; Paul T; Zolk O
Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
[No Abstract] [Full Text] [Related]
15. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
17. Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Filipski KK; Pacanowski MA; Ramamoorthy A; Feero WG; Freedman AN
Pharmacogenet Genomics; 2016 Jul; 26(7):334-9. PubMed ID: 27058883
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics: has the time come for pharmacists to embrace and implement the science?
Beier MT; Panchapagesan M; Carman LE
Consult Pharm; 2013 Nov; 28(11):696-711. PubMed ID: 24217190
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 genotype-guided drug therapies: An update on current states.
Dong AN; Tan BH; Pan Y; Ong CE
Clin Exp Pharmacol Physiol; 2018 Oct; 45(10):991-1001. PubMed ID: 29858511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]